Type2 diabetes Mellitus
Conditions
Interventions
SGLT2 inhibitor(Luseogliflozin)
Amaryl(glimepiride)
Sponsors
Toho University Sakura Medical Center.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Type2 diabetic patients 2)Patients whose BMI is over 25 and HbA1c is over 7.0% but under 8.5% 3)Patients using Biguanide, DPP4 inhibitor and/or GLP1 analog(it doesn't matter any dose)
Exclusion criteria
Exclusion criteria: 1)Type1 diabetic patients or IDDM 2)Patients using insulin 3)Patients had cardiovascular disease or cerebrovascular disease in the past 4)Patients who are judged to be inadequate to use SGLT2 inhibitor 5)Patients with severe infections, patients before or after operations orhaving seriousexternal injuries 6)Patients with allergy to the ingredient(s) of these medicines(Luseogliflozin or amaryl) 7)Patients with severe renal dysfunction or end-stage renal disease undergoing artificial dialysis 8)Patients with severe liver dysfunction 9)Patients with 10)Pregnant women or lactating women 11)Patients who are judged to be inadequate to participate in this study by a doctor in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We evaluate the variations of HbA1c and CAVI from the begining of treatment to week 24. | — |
Secondary
| Measure | Time frame |
|---|---|
| We evaluate the variations of the following items from the begining of treatment to week 24. Hight,body weight,girth of the abdomen,blood pressure,inbody,ABI,fasting plasma glucose,IRI,TC,TG,LDL-C,HDL-C,LPLmass,d-ROMs,keton body,urinalysis(general,glucose and albumin) | — |
Countries
Japan
Contacts
Public ContactIchiro Tatsuno
Toho University Sakura Medical Center. Center of Diabetes, Endocrinology and Metabolism
Outcome results
None listed